2025 Erdafitinib: Prospects and Market Analysis of Targeted Drugs for Precision Treatment of Bladder Cancer

In 2025, Erdafitinib (Erdafitinib), as the world's first approved FGFR inhibitor, continues to trigger revolutionary breakthroughs in the field of precision cancer treatment. This oral targeted drug developed by Johnson & Johnson has established a benchmark position in the treatment of urothelial cancer (mUC; bladder cancer) by virtue of its ability to accurately target tumors with FGFR gene mutations.

xa0

1. Breakthrough efficacy of erdafitinib inFGFR mutated urothelial carcinoma

The phase III THOR trial data released in 2025 further consolidates the core position of erdafitinib in urothelial cancer. The study included 266 metastatic patients carrying FGFR3/2 mutations. The results showed that the median overall survival (OS) of the erdafitinib group was 12.1 months, which was significantly longer than that of the chemotherapy group (7.8 months), and the risk of death was reduced by 36%; the objective response rate (ORR) was as high as 45.6%, far exceeding the 11.5% of the chemotherapy group. It is particularly noteworthy that in the subgroup of patients with brain metastases, erdafitinib demonstrated an intracranial response rate of 25%, providing a new solution to the problem that traditional chemotherapy is difficult to achieve.

Mechanism analysis: Erdafitinib blocks tumor cell proliferation signals by inhibitingFGFR1-4 kinase activity. At the same time, it inhibits RET, CSF1R and other bypass kinases, further inhibiting the release of immunosuppressive factors in the tumor microenvironment.

xa0

2. Analysis of global market prices and medical insurance policies in 2025

Erdafitinib (trade name: Boco) has been on the market for a relatively short time in China. It is currently mainly sold by the Hong Kong version of the original drug, with a price of more than 20,000 yuan. The price of the original drug in the US market is about US$5,000 (4mg specification). In comparison, the prices of foreign generic drugs (such as the Laos version and the Bangladeshi version) are relatively cheap, ranging from a few hundred to two thousand yuan. Although generic drugs cost less, patients still rely on genetic testing and physician guidance to ensure accurate treatment.

1. Medical insurance and price issues: Although erdafitinib has not yet been included in medical insurance in China, with the accumulation of more clinical data and therapeutic effects, it is expected that the drug will be gradually included in medical insurance in the future, further promoting its market popularity.

2. Competition from generic drugs: The emergence of generic drugs provides patients with more economic choices, which may have a certain impact on the market share of original drugs. However, the consistency of drug ingredients and the guarantee of efficacy are still important considerations in patient selection.

xa0

3. Indications and clinical applications of erdafitinib

In January 2025, erdafitinib was officially approved by the China National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic urothelial cancer carrying FGFR3 or FGFR2 gene mutations. This indication is strictly limited to:

1. Gene mutation type: only for tumors with FGFR2 or FGFR3 mutations, fusions or amplifications;

2. Treatment stage: disease progression must occur during or after at least first-line anti-PD-1/PD-L1 treatment;

3. Surgical status: cases that are unresectable by surgery.

The drug can accurately select patients who match specific gene mutations, thereby greatly improving the specificity and effectiveness of treatment. Currently, FGFR gene mutation, as an important molecular marker of bladder cancer, has been included in a number of clinical studies, verifying the therapeutic value of erdafitinib.

Clinical practice emphasizes“No testing, no treatment”—patients must confirm their FGFR mutation status through next-generation sequencing (NGS). According to the THOR study, about 20% of patients with metastatic urothelial cancer carry FGFR mutations, among which FGFR3 S249C mutation is the most common (accounting for 60% of patients with FGFR3 mutations).

xa0

4. Usage and dosage: dose adjustment and treatment monitoring

The dosage regimen of erdafitinib needs to be adjusted according to the individual's condition, tolerance and hematological indicators. At the beginning of treatment, the standard recommended dose is 8 mg taken orally once daily, which can be divided into two 4 mg tablets for patients to take. After 14 to 21 days of treatment, the dose may be increased to 9 mg daily (in three 3 mg tablets) based on serum phosphate levels and adverse effects.

Key monitoring points during treatment include:

1.Monitoring of serum phosphate levels: Erdafitinib may cause hyperphosphatemia, so serum phosphate levels need to be closely monitored during treatment, especially 14 to 21 days after starting treatment.

2. Adverse reaction monitoring: Common side effects of erdafitinib include stomatitis, diarrhea, dry mouth, etc. If serious side effects occur during treatment, the dose needs to be reduced according to the situation.

3. The purpose of dose adjustment is to ensure the efficacy while reducing the occurrence of adverse reactions and improving patient tolerance.

xa0

5. Real-world application challenges and optimization strategies

Real-world data show that common adverse reactions of erdafitinib include hyperphosphatemia (76%), stomatitis (65%) and hand-foot syndrome (48%). Through stepwise dose adjustment (8mg → 9mg) and the use of phosphate binders, more than 90% of patients can tolerate the treatment. It is worth noting that about 25% of patients develop retinal pigment epithelial detachment and require monthly eye examinations.

In 2025, the research boundaries of erdafitinib will continue to expand:

1. Early-stage tumors: In a phase 1 study of non-muscle invasive bladder cancer (NMIBC), erdafitinib combined with Bacillus Calmette-Guérin (BCG) achieved a complete response rate of 90%, and a 12-month recurrence-free rate of 90%;

2. Combination therapy: Combination withPD-1 inhibitors can increase the ORR to 54%, but immune-related adverse reactions need to be closely monitored;

3. Dynamic monitoring: Real-time trackingFGFR mutation status through liquid biopsy technology to achieve personalized treatment adjustment.

xa0

6. Future Development: Clinical Research and Innovation Directions of Erdafitinib

With the continuous development of precision medicine and targeted therapy, the application prospects of erdafitinib in the field of tumor treatment are promising. In the future, more cancer types with FGFR mutations may be included in the indications of erdafitinib, further expanding its therapeutic field. In addition, with in-depth research on the efficacy of drugs at home and abroad, erdafitinib may be combined with other targeted drugs and immunotherapy to produce a synergistic effect and improve the therapeutic effect.

In terms of clinical trials, in the future, it is expected to further verify the efficacy and safety of erdafitinib in different cancer types by expanding the sample size and extending the follow-up time. Nowadays, research on FGFR gene mutations in various types of cancer has been carried out. Erdafitinib may not only be limited to bladder cancer, but may also become a new treatment option for other cancer types.

xa0

7. Conclusion: The future prospects of erdafitinib

As a targeted therapy drug, erdafitinib plays an important role in the precise treatment of tumors such as bladder cancer. Although it is currently relatively expensive and has not yet been included in medical insurance, with the deepening of clinical research and the improvement of the drug management system, erdafitinib is expected to become an important treatment option for more patients. In the future, with the further opening of the domestic market and the improvement of drug availability, erdafitinib has broad market prospects and deserves the attention of patients and the medical community.

References:

Balversa (Erdafitinib) Prescribing Information - U.S. FDA

Erdafitinib for FGFR+ Bladder Cancer - Latest Clinical Data

Erdafitinib in the Treatment of Urothelial Carcinoma - Cancer Therapy Advisor

xa0